Ratings by Jefferies (Eun K. Yang)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/22/2024 | Blueprint Medicines | BPMC | Maintain | Buy (N/A) |
|
Details | ||
| 8/22/2022 | Blueprint Medicines | BPMC | Maintain | Buy (N/A) |
|
Details | ||
| 6/1/2022 | Blueprint Medicines | BPMC | Upgrade | Buy (Hold) |
56.29 (89.84) |
59.6% | Details | |
| 6/23/2021 | Keros Therapeutics | KROS | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2021 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2021 | United Therapeutics Corp. | UTHR | Maintain | Buy (N/A) |
|
Details | ||
| 1/20/2021 | United Therapeutics Corp. | UTHR | Maintain | Buy (N/A) |
|
Details | ||
| 12/8/2020 | United Therapeutics Corp. | UTHR | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2020 | Blueprint Medicines | BPMC | Downgrade | Hold (Buy) |
106.84 (129.46) |
21.17% | Details | |
| 8/19/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2020 | Keros Therapeutics | KROS | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2020 | AMAG Pharmaceuticals | AMAG | Maintain | Hold (N/A) |
|
Details | ||
| 7/30/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Hold (N/A) |
|
Details | ||
| 7/14/2020 | Blueprint Medicines | BPMC | Maintain | Buy (N/A) |
|
Details | ||
| 6/25/2020 | United Therapeutics Corp. | UTHR | Maintain | Buy (N/A) |
|
Details | ||
| 5/11/2020 | AMAG Pharmaceuticals | AMAG | Maintain | Hold (N/A) |
|
Details | ||
| 5/11/2020 | AMAG Pharmaceuticals | AMAG | Maintain | Hold (N/A) |
|
Details |
